Session Details
[JS14★☆]"September 30th is a Day of Infamy for Drug Safety" —Let's Search for evidence in Japan—
Sun. Mar 29, 2026 1:10 PM - 3:10 PM JST
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Room 03 (E201, Bldg. 3, Area 2 [2F])
Organizer: Kazunobu Takayanagi (Kurashiki Cent. Hosp. Pharm.), Masayo Komoda (CNGH, Pharmacy Dept.), Seiko Miyazaki (Teikyo Heisei Univ., Fac. Pharm. Sci.)
Co-sponsored by:
The Pharmaceutical Society of Japan,
Japanese Society of Drug Safety
The Pharmaceutical Society of Japan,
Japanese Society of Drug Safety
On that date in 2004, Merck announced that rofecoxib doubled the risk of myocardial infarction and stroke, and the company withdrew the drug from the market after 5 years of use in more than 20 million patients. This incident showed that even widely used medicines can have serious risks, and triggered a review of pharmacovigilance practices around the world. However, even now, it is difficult to say that this information is being shared effectively between patients and medical professionals, and between government and pharmaceutical companies.
This symposium will first listen to patients' voices, then reflect on the rofecoxib incident and consider early detection measures for drug risks from the perspectives of biostatistics and healthcare policy. Next, we will introduce initiatives to prevent and detect serious adverse drug reactions in patients through pharmacokinetic-based dosing and prescription optimization utilizing academic detailing, with the aim of contributing to search for evidence in the future.
This symposium will first listen to patients' voices, then reflect on the rofecoxib incident and consider early detection measures for drug risks from the perspectives of biostatistics and healthcare policy. Next, we will introduce initiatives to prevent and detect serious adverse drug reactions in patients through pharmacokinetic-based dosing and prescription optimization utilizing academic detailing, with the aim of contributing to search for evidence in the future.
オーガナイザー挨拶
髙栁 和伸（倉敷中央病院薬）
[JS14-1]Are patients' voices being heard by all of us?
○Ikuko Yamaguchi1 (1. COML)
[JS14-2]What Happened in the United States on September 30 — From the Perspective of a Biostatistical Advisor
○Masayoshi Koinuma1 (1. Teikyo Heisei Univ., Fac. Pharm. Sci.)
[JS14-3]Drug Safety Measures using MIHARI Project
○Katsuhiko Ichimaru1 (1. PMDA Pharmacovigil.1)
[JS14-4]Pharmacist's role in prevention and early detection of acyclovir-induced encephalopathy
○Shohei Matsuda1 (1. Dep. of Pharm., Chugoku Rosai Hosp.)
[JS14-5]Academic detailing for physicians toward generating evidence to optimize prescribing
○Natsuko Sugiyama1 (1. Fac. Pharm., Int. Univ. of Health and Welfare)